UroGen Pharma (URGN) Tops Q1 EPS by 12c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. META
5. FFAI
6. FFR
7. AZN
8. CART
9. LLY
10. TSLA

Go back to UroGen Pharma (URGN) Tops Q1 EPS by 12c, Revenues Miss

UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments

May 13, 2021 7:30 AM EDT

Jelmyto® net product revenue of $7.5 million for the first quarter of 2021 New patient starts in March and April of 2021 increased 100% and 165%, respectively, compared to new patient starts in January 2021 Phase 3 ATLAS trial enrollment ongoing with new sites activated in Europe Active platform expansion in immuno-oncology with commencement of strategic collaborations with leading academic institutions Conference call and webcast to be held today at 8:30 AM ET

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company... More